Uwe MASKOS

Prof. Uwe MASKOS


Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 November 2008 in The Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
SPS. Pons
S. Pons
LFLiana Fattore
Liana Fattore
GCG. Cossu
G. Cossu
Stefania ToluStefania Tolu
Stefania Tolu
EPE. Porcu
E. Porcu
WFW. Fratta
W. Fratta
The identification of the molecular mechanisms involved in nicotine addiction and its cognitive consequences is a worldwide priority for public health. Novelin vivoparadigms were developed to match this aim. Although the β2 subunit of the neuronal nicotinic acetylcholine receptor (nAChR) has been shown to play a crucial role in mediating the reinforcement properties of nicotine, little is known about the contribution of the different α subunit partners of β2 (i.e., α4 and α6), the homo-pentameric α7, and the brain areas other than the ventral tegmental area (VTA) involved in nicotine reinforcement. In this study, nicotine (8.7–52.6 μg free base/kg/inf) self-administration was investigated with drug-naive mice deleted (KO) for the β2, α4, α6 and α7 subunit genes, their wild-type (WT) controls, and KO mice in which the corresponding nAChR subunit was selectively re-expressed using a lentiviral vector (VECmice). We show that WT mice, β2-VECmice with the β2 subunit re-expressed exclusively in the VTA, α4-VECmice with selective α4 re-expression in the VTA, α6-VECmice with selective α6 re-expression in the VTA, and α7-KO mice promptly self-administer nicotine intravenously, whereas β2-KO, β2-VECin the substantia nigra, α4-KO and α6-KO mice do not respond to nicotine. We thus define the necessary and sufficient role of α4β2- and α6β2-subunit containing nicotinic receptors (α4β2*- and α6β2*-nAChRs), but not α7*-nAChRs, present in cell bodies of the VTA, and their axons, for systemic nicotine reinforcement in drug-naive mice.

23 January 2017 in Nature Medicine
Verified
Journal Article
Open access
PDF file
FKFani Koukouli
Fani Koukouli
MRMarie Rooy
Marie Rooy
DTDimitrios Tziotis
Dimitrios Tziotis
KSKurt A Sailor
Kurt A Sailor
HOHeidi C O'Neill
Heidi C O'Neill
UMUwe MASKOS
Uwe MASKOS
In transgenic mouse models of neuropsychiatric disease, loss of nicotinic cholinergic signaling in cortical inhibitory interneurons causes neurocognitive behavioral deficits and reduced neuronal activity in prefrontal circuits. Chronic administration of nicotine can restore this cortical hypofrontality phenotype. The prefrontal cortex (PFC) underlies higher cognitive processes1 that are modulated by nicotinic acetylcholine receptor (nAChR) activation by cholinergic inputs2. PFC spontaneous default activity3 is altered in neuropsychiatric disorders4, including schizophrenia5—a disorder that can be accompanied by heavy smoking6. Recently, genome-wide association studies (GWAS) identified single-nucleotide polymorphisms (SNPs) in the human CHRNA5 gene, encoding the α5 nAChR subunit, that increase the risks for both smoking and schizophrenia7,8. Mice with altered nAChR gene function exhibit PFC-dependent behavioral deficits9,10,11, but it is unknown how the corresponding human polymorphisms alter the cellular and circuit mechanisms underlying behavior. Here we show that mice expressing a human α5 SNP exhibit neurocognitive behavioral deficits in social interaction and sensorimotor gating tasks. Two-photon calcium imaging in awake mouse models showed that nicotine can differentially influence PFC pyramidal cell activity by nAChR modulation of layer II/III hierarchical inhibitory circuits. In α5-SNP-expressing and α5-knockout mice, lower activity of vasoactive intestinal polypeptide (VIP) interneurons resulted in an increased somatostatin (SOM) interneuron inhibitory drive over layer II/III pyramidal neurons. The decreased activity observed in α5-SNP-expressing mice resembles the hypofrontality observed in patients with psychiatric disorders, including schizophrenia and addiction5,12. Chronic nicotine administration reversed this hypofrontality, suggesting that administration of nicotine may represent a therapeutic strategy for the treatment of schizophrenia, and a physiological basis for the tendency of patients with schizophrenia to self-medicate by smoking13.

3 December 2013 in Molecular Psychiatry
Verified
Journal Article
Closed access
PDF file
CMC Morel
C Morel
LFLiana Fattore
Liana Fattore
SPS Pons
S Pons
YHY A Hay
Y A Hay
FMF Marti
F Marti
PFP Faure
P Faure


14 October 2008 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
MAMaria Elena Avale
Maria Elena Avale
PFPhilippe Faure
Philippe Faure
SPStéphanie Pons
Stéphanie Pons
PRPatricia Robledo
Patricia Robledo
TDThierry Deltheil
Thierry Deltheil
UMUwe MASKOS
Uwe MASKOS
Acetylcholine (ACh) is a known modulator of the activity of dopaminergic (DAergic) neurons through the stimulation of nicotinic ACh receptors (nAChRs). Yet, the subunit composition and specific location of nAChRs involved in DA-mediated locomotion remain to be established in vivo . Mice lacking the β2 subunit of nAChRs (β2KO) display striking hyperactivity in the open field, which suggests an imbalance in DA neurotransmission. Here, we performed the selective gene rescue of functional β2*-nAChRs in either the substantia nigra pars compacta (SNpc) or the ventral tegmental area (VTA) of β2KO mice. SNpc rescued mice displayed normalization of locomotor activity, both in familiar and unfamiliar environments, whereas restoration in the VTA only rescued exploratory behavior. These data demonstrate the dissociation between nigrostriatal and mesolimbic β2*-nAChRs in regulating unique locomotor functions. In addition, the site-directed knock-down of the β2 subunit in the SNpc by RNA interference caused hyperactivity in wild-type mice. These findings highlight the crucial interplay of nAChRs over the DA control of spontaneous locomotion.

26 October 2009 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
Stefania ToluStefania Tolu
Stefania Tolu
MAM. Elena Avale
M. Elena Avale
HNHiroko Nakatani
Hiroko Nakatani
SPStephanie Pons
Stephanie Pons
SPSebastien Parnaudeau
Sebastien Parnaudeau
UMUwe MASKOS
Uwe MASKOS
Lentiviral expression vectors are powerful tools for gene therapy and long‐term gene expression/repression in the mammalian brain. However, no specificity of transduction has been reported so far in the central nervous system. Here we have developed a novel system to achieve a neuronal subtype specific expression in either dopaminergic (DA) or GABAergic neurons. We employed a delivery strategy by which the transgene is not expressed until its activation by Cre recombinase. We successfully tested the system in vitro and then used this novel lentivector, containing lox P sites, in 2 different transgenic mouse lines expressing Cre either in DA or in GABAergic neurons. In both lines the reporter gene was detected exclusively in Cre‐positive cells, demonstrating that with this experimental approach we were able to achieve completely specific expression of transgenes delivered by lentiviral vectors. This universal system can be applied to all neural subtypes making use of the growing number of specific Cre driver lines.—Tolu, S., Avale, M. E., Nakatani, H., Pons, S., Parnaudeau, S., Tronche, F., Vogt, A., Monyer, H., Vogel, R., de Chaumont, F., Olivo‐Marin, J.‐C., Changeux, J.‐P., Maskos, U. A versatile system for the neuronal subtype specific expression of lentiviral vectors. FASEB J. 24, 723–730 (2010). www.fasebj.org